"One week Jun" Chinese medicine tablets into the traceability system; JD.com, the Post Office of the pharmaceutical circulation market; Russia took the lead in the development of a new crown vaccine successfully controversial; Fortune 500 Chinese enterprises the number of the first over the United States.

Guide: This week the new crown vaccine on the hot search, Russian vaccine research and development success? Micro-commerce ahead of the "selling" ... . . . this week to see: 1. Chinese medicine tablets into the traceability system 2. JD., postal into the pharmaceutical circulation 3. Russia took the lead in the research and development of a new crown vaccine successfully caused controversy 4. Fortune 500 Chinese enterprises first over the U.S. pharmaceutical circulation market change! JD.k., Post Office August 11, Shaanxi Provincial Drug Administration issued "on the approval of Shaanxi Jingdong Pharmaceutical Supply Chain Management Co., Ltd. to apply for third-party drug logistics filing qualifications."
its Chinese shows: "In order to speed up the development of the pharmaceutical logistics industry in our province, it was agreed that Shaanxi Jingdong Pharmaceutical Supply Chain Management Co., Ltd. and Shaanxi Haichuan Pharmaceutical Logistics Co., Ltd. in the state-level new area - Xi xian New Area first trial implementation of the strategic cooperation model."
agreed to Shaanxi Jingdong Pharmaceutical Supply Chain Management Co., Ltd. to carry out third-party pharmaceutical logistics business.
" that is, JD.p. as a third-party drug logistics, perhaps to a large extent will affect the existing pharmaceutical circulation in the field of market patterns, cross-changing.
Chinese medicine tablets into the traceability system! The first batch of 20 selected pharmaceutical wholesale enterprises on August 11, Hebei Province Drug Administration official website issued "on the promotion of drug circulation traceability system drug tablets traceability work notice" (hereinafter referred to as "Notice"), a batch of Chinese medicine tablets into the drug circulation traceability system, and selected 20 pharmaceutical wholesale enterprises for Chinese medicine tablets standard data control and traceability data upload work.
analysts believe that the perfection of Chinese medicine tablets traceability, the soundness of the traceability system can greatly reduce the occurrence of "errors", so that the Chinese medicine tablets into the scope of monitoring Hebei drug traceability system, on the first batch of drug wholesale enterprises and video transmission conditions mature enterprises trial video transmission off-site monitoring, enterprise warehouse video surveillance access to drug circulation off-site monitoring system, drug regulatory authorities can real-time view of pharmaceutical enterprises warehouse video surveillance.
up-to-date! The National Health And Health Commission met to crack down on medical corruption on August 10, the State Health And Health Commission Medical Administration announced that a few days ago, to correct the field of pharmaceutical purchase and sale and medical services in the wrong wind of the 22nd meeting of the inter-ministerial joint meeting held in Beijing.
meeting called for the 2020 anti-wind work to continue to crack down on fraud and fraud of health insurance funds, consolidate the effectiveness of the field of medical circulation, resolutely clean up the industry chaos, actively respond to the epidemic prevention and control risk points, to ensure that the work is effective.
a new round of wind-correction work, continue.
Russia's first approval of the new crown vaccine caused a thousand waves, what should be concerned about the follow-up? On August 11th Russia was the first country to announce that the world's first new crown vaccine had been approved by the drug regulatory authorities.
rock stirred up a thousand waves, the news caused a great stir.
from the WHO to government officials, from vaccine experts to drug regulatory agencies, have evaluated the world's first vaccine.
most countries have expressed doubts about the effectiveness of the vaccine in Russia because no Russian clinical data have been seen in a series of published information, making the effectiveness of the vaccine difficult to judge at this time.
the FDA has reduced the protective effect of the new vaccine to an acceptable minimum of 50 percent because of the urgency and time constraints of the outbreak.
if this level is not met, the potential benefits and risks of the vaccine need to be reassessed.
, the WHO launched an investigation into the new vaccine immediately after Russia announced its approval.
to seek a range of supporting evidence for the vaccine.
the development of the "new crown vaccine" is responsible not only to the Russian people, but also to those of other countries eager to get the vaccine.
break through! On August 10th Fortune magazine released its latest list of the world's top 500 companies, with 21 pharmaceutical companies named this year, four of which are among the first to appear: Takeda Pharmaceuticals, Shanghai Pharmaceuticals, BMS and Somerset.
Fortune 500, which has been hailed as the "ultimate list" by people from all walks of life, is one of the most famous lists of the world's largest companies, and its authority can be said to have reached its peak.
the list, which is based on revenues, reached a record $33 trillion this year, a staggering sum close to the combined GDP of china and the United States.
the threshold for entry into the rankings (minimum sales revenue) was also raised from $24.8 billion to $25.4 billion.
and this year's most eye-catching change is undoubtedlyChinese mainland the company has achieved a historic leap: Chinese mainland (including Hong Kong) companies reached 124, the first time in history more than the United States (121).
addition to Companies in Taiwan, 133 companies in China are on the list.
, there are eight new companies on the list: Shanghai Construction Industry, Shenzhen Investment Holdings, Shenghong, Shandong Iron and Steel, Shanghai Pharmaceuticals, Guangxi Investment, China's nuclear industry and China Coal Energy.
pharmaceutical industry as an outstanding representative of the list, from then on, China Pharmaceutical Group is finally no longer lonely.
's ranking has also been moving forward, up 24 places from last year to 145th place in the TOP150.
vaccine for the development of success, micro-business first a few days ago, the circle of friends of micro-business suddenly sold a number of new crown vaccine, triggering widespread discussion on the Internet, once dominated the micro-blogging hot search, after the Shanghai network and other media issued rumors.
according to the media, the first vaccine called the "Krive new coronavirus inactivated vaccine (Vero cells)," the approval number under its packaging shows pending.
trace the barcodes on the scanned packaging, the vaccine can be found in the production company is Beijing Coxing Zhongwei Biotechnology Co., Ltd.
the new coronavirus inactivated vaccine (Vero cells), which is manufactured by Wuhan Institute of Biological Products Co., Ltd.
Beijing Kexing Zhongwei Biotechnology Co. , Ltd. related to the person in charge, "Kerrafu new coronavirus inactivated vaccine (Vero cells)" is currently in Brazil, Bangladesh and other countries for three phases of clinical research, has not yet been listed.
new coronavirus inactivated vaccine (Vero cells)" is still in clinical trials and is not on the market, said the person in charge of Wuhan Biological Products Research Institute Co., Ltd.
, neither of the new crown vaccines is on the market.
there is no such thing as a person who can be vaccinated first.
billion! On August 12, Treasure Island Pharmaceuticals announced that the total amount of funds to be raised from the proposed non-public offering of shares will not exceed 208,109.05 million yuan - the net amount of funds raised will be used for innovative drugs and generic drug research and development platform projects, the third phase of the Chixi Branch project construction project, the processing project of Chinese herbal medicine production, information upgrading construction projects and supplementary working capital.
, the company is expected to invest 1.3 billion yuan in innovative drug and generic drug research and development platform projects.
according to Treasure Island Pharmaceuticals' 2019 results, in 2019, while continuing to focus on promoting the research and development of Chinese medicines, it will also vigorously promote the process of generic drugs, innovative drug research, production and marketing.
in particular, it has strengthened research and development of chemical drugs for the domestic market- including 3 innovative drugs in research and development, 42 generic drugs and 2 consistency evaluation projects.
previous public information, Treasure Island Pharmaceuticals has said that its research and development work is gradually from traditional Chinese medicine to the field of chemical and biological medicine.
Renren Biotech Board IPO will promote the development of 6 innovative products August 13, Shanghai Renren Biopharmaceutical Co., Ltd. (herein: Renren Bio) in the Shanghai Stock Exchange Science and Technology Board IPO application has passed the Shanghai Municipal Committee meeting, the sponsor institution is Guotai Junan.
the prospectos, the IPO is expected to raise 3,005 million yuan, of which about 1.24 billion yuan will be used for new drug research and development projects.
, the company's first innovative biopharmaceutical, Benaglutide Injection, has been commercialized primarily for the treatment of type 2 diabetes.
Concino Bio today landed on the Board to become the first "A-H" vaccine shares august 13, Conschino Bio AG ("Conschino Bio") successfully landed on the Board, becoming the first "A-H" vaccine shares.
24.8 million shares at a price of 209.71 yuan.
it is understood that the funds raised will be used for the second phase of production base construction, vaccine research and development, vaccine traceability, cold chain logistics system and information system construction and supplementary liquidity.
but consino's profitability is still in the early stages of commercialization, and the main products have not yet achieved scale revenue.
's 2017-2019 operating income was 187.2 million yuan, 2.8119 million yuan and 2.2834 million yuan, respectively, the product is still in the pre-commercialization research and development stage, vaccine products are not listed for sale, only generating occasional other business income.
In this moment, compared to the choice of Consino, the market may be more inclined to be able to afford the domestic large-scale market and industrialization capacity of strong vaccine manufacturers, Kantai Biological, Zhifei Biological, Hualan Biological, Watson Bio, etc. as a leading enterprise is not only the first half of the number of vaccine issues, but also a large share of the industry market, will undoubtedly attract more investors.
, a painkiller safer than morphine, was approved by the U.S. Food and Drug Administration (FDA) on Aug. 8 for the treatment of moderate to severe acute pain in adults.
August 10, Enhua Pharmaceuticals confirmed this news with an announcement that Enhua and Trevena Corporation of the United States ("Trevena") signed a cooperation agreement at the end of April 2018 on the exclusive licensing and commercialization of Class 1 chemical TRV-130 injections in China for "authorized indications".
June 3, 2020, Jiangsu Enhua has received approval from China's State Drug Administration (NMPA) to begin clinical trials of Olinvyk for intravenous injections.
Olinvyk's approval in China is now pending with Olinvyk's approval at the FDA.
for Enhua Pharmaceuticals, once the market feedback is good, heavy products to fill in another member, further expand the market share is also promising.
even the flowers and the plague are on fire again! The first quarter sold more than 1.5 billion more than 10 countries and regions can be sold on August 11, Ealing Pharmaceuticals announced that it received the Philippine Food and Drug Administration approved the issuance of drug registration certificate, approved the company's drug lianhua clear plague capsules in line with the Philippines traditional plant drug standards registration.
the first quarter of 2020, Lianhua Qing plague products revenue of 1,542 million yuan, accounting for 66.07 percent of the company's total revenue.
to date, Lianhua Qing plague capsules have been licensed in more than 10 countries and regions in China, including Hong Kong, Macau and Brazil, Indonesia, Canada, Mozambique, Romania and Thailand.
Ing Pharmaceuticals said that the lianhua clear plague capsule obtained the Philippine Food and Drug Administration's drug registration approval, marking the company's eligibility to sell the product as a drug in the Philippine market, on the whole, the company to expand overseas markets have a positive impact.
information sources: Pharmacy News, Sina Pharmaceutical News, Cypress Blue, E Pharmaceutical Manager, Pharmaceutical Economics, China Pharmaceutical News, Pharmacy Manager, Oriental Wealth Choice Data, Daily Economic News, Interface News, etc. Recommended reading: 1. "A week Jun" domestic and foreign pharmaceutical companies big cattle pile exposure semi-annual report; Sichuan people Fu was sold; Tag Medicine into the 3rd ... 2. "One Week Jun" 18 pharmaceutical companies in the Fortune China 500; anti-tumor drugs reshuffle; the United States to support Kodak ... 3. "One week Jun" three batches of national mining "bottom-up examination" to come; 4. Jun Jun, Junshi opened the market value of more than 150 billion, using "research and development" valuation; 5. "One week Jun" 17 kinds of drugs "turn non-transfer";